The Bio21 Institute is committed to developing industry networks and partnerships. This includes substantial collaborations with major instrument companies, industry Research and Development (R&D) partnerships and space for start-up companies in the Institute's business incubator.

By facilitating strong industry links, the Institute can provide further opportunities for members, from the mentorship for young researchers, the identification of potential technology transfer and commercialisation outcomes that benefit the broader community.

The Bio21 Institute has strategic relationships with a range of industry tenants, from the R&D group of Australia's largest biopharmaceutical company, CSL Limited, to start-up companies residing in the Institute's Incubator.

Current industry tenants

Alterity Biotechnology


Alterity Therapeutics is a company focused on research and development of novel therapeutic compounds to improve the lives of patients with age related disorders.

Circa Group

Established in 2006, Australian company Circa Group converts waste biomass into advanced bio-based chemicals with its proprietary FuracellTM process.  Circa’s broad product portfolio includes biosolvents, flavours and biopolymers, including Cyrene®, an alternative to traditional polar aprotic solvents. 






CSL's Research & Development Group focus on therapeutic discovery.

Gertrude Biomedical


Gertrude Biomedical is a biotechnology company dedicated to developing novel small molecule inhibitors of the SOX18 transcription factor complex for the treatment of serious human diseases, which depend on aberrant vasculature for their growth and spread.

Rhythm Biosciences

Rhythm Biosciences is interested in developing and commercialising Australian medical diagnostics technology for sale to national and international markets.
For Rhythm Biosciences, ColoSTAT™ is the first proposed product-in-development, intended as a test for the accurate and early detection of colorectal cancer.
Whether used as a ‘first-step’ screening test or in the triage of persons with a positive FIT to colonoscopy, ColoSTAT™ could play an important role in reducing the morbidity, mortality and healthcare costs associated with colorectal cancer.
ColoSTAT™ is envisaged as a simple, affordable and effective diagnostic ‘first step’ test to augment any national, state or philanthropic screening programs. This test may be of value to those people who are at risk of developing colorectal cancer, particularly those who choose not to participate in standard screening programs for various reasons.

SYNthesis med chem & SYNthesis Research

SYNthesis Research is a small molecule drug discovery company focussing on both early-stage deal flow and strategic longer-term clinical development programs. Headquartered in Melbourne Australia, SYNthesis Research maximises the benefits of the favourable Australian R&D environment to progress its Drug Discovery & Development portfolio. It does this by leveraging its exceptional Innovation Network - An integrated, federated Australian-Chinese R&D network optimised to provide non-dilutive R&D services to the company’s programs, at costs up-to 60% lower than other global locations.

SYNthesis med chem, founded in 2007, is a relatively new player in the chemistry CRO market. We are Australian owned with laboratory facilities in Shanghai China and offices in Australia, the US and the UK. The management team at SYNthesis are experienced drug discovery professionals with expertise across a range of targets (particularly Kinases, GPCRs and epigenetic targets).

Past industry tenants

The Women's Hospital Centre for Women's Infectious Diseases

The Women's Hospital Centre for Women's Infectious Diseases conducts clinical research and cutting edge molecular diagnostics in the research areas of reproductive and sexual health, and neonatal  infectious diseases.

BioScreen Medical - Microbial diagnostics.

Sienna Cancer Diagnostics - Molecular biomarkers for specific tumours.

Patrys Ltd - Therapeutic Antibodies against Cancer